Connection
Gregory Schwartz to Acute Disease
This is a "connection" page, showing publications Gregory Schwartz has written about Acute Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.247 |
|
|
|
-
Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct; 28(10):2508-13.
Score: 0.052
-
Schwartz GG. Statins in acute coronary syndromes: the sooner, the better? Am Heart J. 2005 Mar; 149(3):377-80.
Score: 0.050
-
Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003 Nov 01; 92(9):1109-12.
Score: 0.046
-
Schwartz GG. Exploring new strategies for the management of acute coronary syndromes. Am J Cardiol. 2000 Oct 19; 86(8B):44J-49J; discussion 49J-50J.
Score: 0.037
-
Greyson C, Xu Y, Cohen J, Schwartz GG. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res. 1997 May; 34(2):281-8.
Score: 0.029
-
Ahmad HA, Lu L, Ye S, Schwartz GG, Greyson CR. Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. Am J Respir Cell Mol Biol. 2012 Sep; 47(3):379-86.
Score: 0.021
-
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6.
Score: 0.011